![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/9/98/Spironolactone.svg/640px-Spironolactone.svg.png&w=640&q=50)
Mineralocorticoid receptor antagonist
Drug class / From Wikipedia, the free encyclopedia
A mineralocorticoid receptor antagonist (MRA or MCRA)[1] or aldosterone antagonist, is a diuretic drug which antagonizes the action of aldosterone at mineralocorticoid receptors. This group of drugs is often used as adjunctive therapy, in combination with other drugs, for the management of chronic heart failure. Spironolactone, the first member of the class, is also used in the management of hyperaldosteronism (including Conn's syndrome) and female hirsutism (due to additional antiandrogen actions). Most antimineralocorticoids, including spironolactone, are steroidal spirolactones. Finerenone is a nonsteroidal antimineralocorticoid.
Quick Facts Class identifiers, Synonyms ...
Mineralocorticoid receptor antagonist | |
---|---|
Drug class | |
![]() Spironolactone, the most widely used antimineralocorticoid. | |
Class identifiers | |
Synonyms | Aldosterone antagonistic; Mineralocorticoid antagonist |
Use | Diuretic; Chronic heart failure; Hypertension; Hyperaldosteronism; Conn's syndrome |
Biological target | Mineralocorticoid receptor |
Chemical class | Steroidal; Nonsteroidal |
Legal status | |
In Wikidata |
Close